Sitafloxacin

DB13261InvestigationalSmall molecule

Sitafloxacin is a fluoroquinolone antibiotic indicated in the treatment of susceptible bacterial infections. An antibiotic used to treat a wide variety of infections in the body.

Formula / weight: C₃₈H₄₂Cl₂F₄N₆O₉ · 873.68 g/mol (avg)
Code names: DU-6859A

Resolves to

Compound

UNII9TD681796GCAS163253-35-8

Clinical / RWD

ATCJ01MA21

Structure

InChIKeyMPORYQCGWFQFLA-ONPDANIMSA-NSMILES

O.O.O.N[C@@H]1CN(CC11CC1)C1=C(F)C=C2C(=O)C(=CN([C@@H]3C[C@@H]3F)C2=C1Cl)C(O)=O.N[C@@H]1CN(CC11CC1)C1=C(F)C=C2C(=O)C(=CN([C@@H]3C[C@@H]3F)C2=C1Cl)C(O)=O

Targets

P20831gyrAP0A0K8gyrBP0AFI2parC

What you can answer from here — as of March 06, 2025

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

958Drug interactionsStructured to mechanism, not free text

7Clinical trialsPhase, status and sponsor resolved per trial

8Structured indicationsCondition, population, route and combination as fields, not prose

2Marketed productsAcross 1 country and 2 labellers

1ATC codeIncluding every combination product, plus 17 drug categories

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Sitafloxacin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account